echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > JCEM: Thyroid dysfunction induced by immunocheckpoint inhibitors is associated with body mass index.

    JCEM: Thyroid dysfunction induced by immunocheckpoint inhibitors is associated with body mass index.

    • Last Update: 2020-07-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Obesity is an inflammatory metabolic state that may play an important role in the occurrence of adverse immune events (irAE) associated with the treatment of immunocheckpoint inhibitors!----, researchers have published a study in journal Journal of Endocrinology and Clinical Endocrinology and Metabolism, an authoritative journal in the field of endocrine and metabolic diseases, to explore the association between body mass index (BMI) and thyroid irAEresearchers conducted a single-center retrospective of 185 cancer patients treated with anti-PD-1/L1 between January 2014 and December 2018, including patients with baseline thyroid function and available BMI datathe study's main outcome indicator was the BMI difference in patients with significant thyroid insufficiency and normal thyroid function after initiation of anti-PD-1/L1 therapyOther endpointsinclude any (obvious or subclinical) hypothyroidism, apparent thyroid toxicity or apparent hypothyroidism, and the timing of dysfunction based on BMI72 patients (38.9%) developed thyroid dysfunction, of which 41 (22.1%) had significant thyroid dysfunctionthe average BMI of those withthyroid insufficiency was higher than that of normal (27.3 x 6.0 vs24.9 to 4.5, p -0.03)thyroid toxicity was associated with a higher BMI in relation to normal thyroid function (28.9 x 5.9 vs24.9?4.5; p-lt;0.01), and not with significant hypothyroidism (26.7?5.5 vs24.9?4.5, p-0.10)the normal low BMI group developed significant thyroid toxicity within days of starting treatment 57.5 (IQR 31.8-78.8), with super-recombinant 38.0 (IQR 26.8-40.5) days and obesity group 23.0 (IQR 21.0-28.0) days (p.02)thus, patients treated with PD-1/L1 inhibitors are more likely to develop thyroid irAE, especially thyroid toxicity, as their BMI increases, obese patients develop edited thyroid toxicity earlier than in thinner patients these data highlight the complex interaction between obesity and immune response in patients treated with immunocheckpoint inhibitors .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.